Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of matched unrelated versus haploidentical donor allogeneic stem cell transplantation with identical GVHD prophylaxis in acute leukemia and high-risk MDS
NL-OMON52639Active, not recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Dec 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclophosphamide, tacrolimus, mycophenolate mofetil, fludarabine and busulfan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Relapse incidence at 2 years. Started Dec 2023; status: active, not recruiting.
02
Drugs
cyclophosphamidetacrolimusmycophenolate mofetilfludarabinebusulfan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON52639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52639.